Guardians of immunity: the role of tumour-draining lymph node in cancer immunity
Authors:
Open Access
- 22 May 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1816042
Abstract
The success of immunotherapies in cancer has changed the landscape of cancer research. The tumour-draining lymph node (TDLN) is emerging as an organ specific target to enhance the efficacy and minimize the toxicity of immunotherapies; this approach is based on the TDLN being the first lymph node to encounter metastatic tumour cells and various tumour-derived factors. Both anti-tumour and immunosuppressive T cells can originate from the TDLNs. Accumulating evidence has shown that immunosuppressive T cells are activated in the TDLN before migrating to the tumour to perform their functions. This suggests that targeting the TDLN could be crucial for intercepting immunosuppressive T cells and enhancing immunotherapy. Notably, regional delivery of ICI drugs to the TDLN has been shown to achieve similar outcomes to systemic delivery but with reduced toxicity to the host. T cell immunity is well-known to be regulated by dendritic cells (DCs) in cancer. However, B cells, which form a significant population of immune cells in the TDLNs, have emerging roles in this regulation. This review seeks to elucidate the mechanisms of cancer immunity within the TDLN and to explore the potential role of B cells in immunotherapies.Keywords
This publication has 160 references indexed in Scilit:
- LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunityCell, 2024
- Circulating soluble CD30 is associated with renal tertiary lymphoid structures and the progression of IgA nephropathyClinica Chimica Acta, 2024
- Single‐cell transcriptome sequencing of B‐cell heterogeneity and tertiary lymphoid structure predicts breast cancer prognosis and neoadjuvant therapy efficacyClinical and Translational Medicine, 2023
- A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunityCancer Cell, 2023
- Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responsesCell, 2021
- The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph NodesCancer Cell, 2020
- The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillanceJournal of Leukocyte Biology, 2020
- Adenosine-producing regulatory B cells in head and neck cancerCancer Immunology, Immunotherapy, 2020
- Origin and development of classical dendritic cells2019
- Critical Role for CD103+/CD141+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in MelanomaCancer Cell, 2016